2026-04-23 15:21:28 UTC / 路透社
路透社报道
2026年4月23日 美国东部时间下午3:21 更新于31分钟前
节点运行失败
2022年4月20日，美国加利福尼亚州旧金山金门公园举行的420嬉皮山音乐节上，一名男子传递大麻烟卷。路透社/卡洛斯·巴里娅 资料图片 购买授权，打开新标签页
4月23日（路透社）——美国司法部即将放松对部分大麻产品的限制，并加快将该毒品重新归类为低危险性物质的进程，这是数十年来美国毒品政策最重大的变革之一。
周四，特朗普政府将美国食品药品监督管理局批准的大麻产品以及州监管的医用大麻从一类被列为高度成瘾的药品，调整为具有低至中度滥用潜力的类别。
通过每日案卷新闻简报获取最新法律资讯，开启您的晨间阅读。点击此处订阅。
广告 · 滚动继续
以下是企业高管和政策专家的部分评论：
欧文·西蒙（IRWIN SIMON）， Tilray Brands首席执行官
“重新分类有望加速临床研究、扩大可及性，并提升质量、一致性和安全标准，从而确立医用大麻作为现代医疗体系合法组成部分的地位。”
金·里弗斯（KIM RIVERS）， Trulieve首席执行官
“这传递出一个信号：大麻不应与海洛因归为同一类别，且明确承认大麻符合第三类管制药品的标准，即存在可接受的医用用途。”
伊内萨·波诺马廖娃特（INEsa PONOMARIOVAITE）， NESA’S HEMP创始人兼首席执行官
“如果此次转型要真正带来公共健康益处，就必须配套建立以数据为依据的标准、加强对内源性大麻素系统的科普，以及在医疗保健、监管机构和行业之间建立更协作的合作模式。”
广告 · 滚动继续
阿拉斯·阿扎迪安（ARAS AZADIAN）， Avicanna首席执行官
“自最初的行政令发布以来，我们一直在为美国大麻重新分类后的市场格局做准备，把握推进研发、临床开发的机遇，并将我们在加拿大成熟的大麻素药物平台拓展至美国市场。”
梅利莎·斯特吉斯（MELISSA STURGESS）， Ananda Pharma首席执行官
“对Ananda而言，这意味着我们可以加快临床试验进度，并计划推出一款获批的CBD类药物，用于治疗子宫内膜异位症引发的疼痛。数百万深受这种衰弱病症折磨的女性，理应获得一种非激素类的治疗方案来缓解痛苦。”
特里·门德斯（TERRY MENDEZ）， Safe Harbor Financial首席执行官
“我们预计，此次举措加上目前正在审议的更广泛的大麻重新分类工作，将吸引更多银行和信用合作社的关注。随着联邦层面感知风险的降低，将有更多金融机构探索大麻银行业务，为合规的技术赋能解决方案拓展潜在市场。”
安东尼·科尼利奥（ANTHONY CONIGLIO）， NewLake Capital Partners首席执行官
“这只是一项部分性措施，而非全面改革。该行政令并未涵盖成人用大麻，未在联邦层面合法化大麻，也未解决行业面临的银行服务难题。更广泛的重新分类程序仍然至关重要，即将举行的药品 Enforcement管理局听证会应加快推进，以便市场能够获得期待已久的明确政策。”
贝蒂·奥尔德沃思（BETTY ALDWORTH）， 多学科迷幻剂研究与教育协会联合执行主任、大麻政策项目主席
“如果本届政府真的致力于改革，就必须超越重新分类，解决刑事定罪、因逮捕记录导致的终身限制以及金融排斥问题。任何不够彻底的举措，都将继续让患者、医疗从业者和社区——尤其是那些受禁令伤害最深的群体——等待从未真正落地的变革。”
布雷特·舒曼（BRETT SCHUMAN）， 古德温律师事务所大麻业务联合主席
“我们不能忘记，仍有许多人因非暴力大麻相关罪行在联邦监狱服刑终身或长期徒刑。此次联邦法律的修改，要求对这些刑期进行重新审查，并在大多数情况下予以减刑。”
马克·刘易斯（MARK LEWIS）， LUT特种支付部门总裁
“药房运营商仍需解决如何支付员工薪酬、如何在不中断的情况下接收付款，以及如何在尚未完全支持其业务的体系中维持现金流的问题。这不会在一夜之间改变，即便实施了大麻重新分类政策也未必能解决。”
由班加罗尔的克里斯蒂·桑托什、斯里帕尔纳·罗伊、米纳利卡·罗伊和普扬·辛格报道；希尔皮·马朱姆达编辑
我们的准则：汤森路透信任原则，打开新标签页
VIEW Cannabis rescheduling fuels optimism across industry
2026-04-23 15:21:28 UTC / Reuters
By Reuters
April 23, 2026 3:21 PM UTC Updated 31 mins ago
节点运行失败
A man passes a marijuana joint during the 420 Hippie Hill festival at Golden Gate Park in San Francisco, California U.S., April 20, 2022. REUTERS/Carlos Barria/File Photo Purchase Licensing Rights, opens new tab
April 23 (Reuters) – The U.S. Department of Justice is immediately loosening restrictions on some marijuana products and accelerating the process of reclassifying the drug as less dangerous in one of the biggest changes to U.S. drug policy in decades.
The Trump administration on Thursday moved FDA-approved marijuana products and state-regulated medical marijuana from a group of drugs classified as highly addictive to one that has a low to moderate potential for abuse.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
Advertisement · Scroll to continue
Here are some comments from company executives and policy experts:
IRWIN SIMON, CEO, TILRAY BRANDS
“Rescheduling has the potential to accelerate clinical research, broaden access and elevate the quality, consistency, and safety standards that establish medical cannabis as a legitimate pillar of modern healthcare.”
KIM RIVERS, CEO, TRULIEVE
“This sends a signal that marijuana should not be in the same classification as heroin, and that there is absolutely an acknowledgement, it’s a requirement for Schedule 3, that there are acceptable medical uses for marijuana.”
INESA PONOMARIOVAITE, FOUNDER AND CEO, NESA’S HEMP
“If this transition is going to deliver real public health benefits, it has to be paired with a commitment to data-driven standards, better education around the endocannabinoid system, and a more collaborative approach across healthcare, regulatory bodies and industry.”
Advertisement · Scroll to continue
ARAS AZADIAN, CEO, AVICANNA
“Since the initial executive order, we have been preparing for what could be a post rescheduling landscape in the U.S. and the opportunities to advance R&D, clinical development and translate our comprehensive platform for cannabinoid-based medicine from Canada into the U.S. market.”
MELISSA STURGESS, CEO, ANANDA PHARMA
“For Ananda, it means we can speed up our clinical trials and plan to bring a licensed CBD-based medicine to market for the treatment of endometriosis pain. The millions of women suffering from this debilitating condition deserve a non-hormonal treatment that will relieve their suffering.”
TERRY MENDEZ, CEO, SAFE HARBOR FINANCIAL
“We expect this action, along with the broader rescheduling effort currently under review, to drive increased interest from banks and credit unions. As perceived federal risk moderates, more institutions are likely to explore cannabis banking, expanding the addressable market for compliant, technology-enabled solutions.”
ANTHONY CONIGLIO, CEO, NEWLAKE CAPITAL PARTNERS
“This is a partial measure, not full reform. The order does not extend to adult-use cannabis, does not legalize marijuana federally, and does not resolve the industry’s banking challenges. The broader rescheduling proceeding remains critically important, and the upcoming DEA hearing process should move forward on an expedited basis so the market can get the clarity it has been waiting for.”
BETTY ALDWORTH, CO-EXECUTIVE DIRECTOR OF MAPS, CHAIR OF THE MARIJUANA POLICY PROJECT
“If this administration is serious about reform, it must go beyond rescheduling to address criminalization, lifelong restrictions due to arrests, and financial exclusion. Anything less will continue to leave patients, providers, and communities, especially those most harmed by prohibition, waiting for change that never fully arrives.”
BRETT SCHUMAN, CO-CHAIR OF CANNABIS PRACTICE AT GOODWIN
“We can’t forget the many people still sitting in federal prison serving life or other lengthy sentences for non-violent cannabis offenses. Today’s change in federal law requires that those sentences be revisited and, in most cases, commuted.”
MARK LEWIS, PRESIDENT OF SPECIALTY PAYMENTS, LUT
“Dispensary operators still have to figure out how to pay employees, how to accept payments without disruption and how to keep cash flow moving in a system that doesn’t fully support your business. That won’t change overnight, if at all with rescheduling.”
Reporting by Christy Santhosh, Sriparna Roy, Mrinalika Roy and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar
Our Standards: The Thomson Reuters Trust Principles., opens new tab
发表回复